Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.44 |
| ▸ | CPB2 | Q96IY4 | 10/20 | 0.36 |
| ▸ | C3AR1 | Q16581 | 1/20 | 0.33 |
| ▸ | VSIR | Q9H7M9 | 2/20 | 0.33 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.33 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.33 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.33 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21168314 | 0.96 | FOLH1 (0.44) | FOLH1CPB2C3AR1VSIRPRSS1 | |
| SCHEMBL24058854 | 0.95 | FOLH1 (0.45) | FOLH1CPB2PRSS1PRSS2PRSS3 | |
| SCHEMBL21168302 | 0.92 | FOLH1 (0.37) | FOLH1C3AR1VSIRCD274 | |
| SCHEMBL24668074 | 0.91 | FOLH1 (0.42) | FOLH1CPB2C3AR1VSIRPRSS1 | |
| SCHEMBL21168361 | 0.90 | FOLH1 (0.41) | FOLH1 | |
| SCHEMBL24058580 | 0.89 | FOLH1 (0.47) | FOLH1 | |
| SCHEMBL23351191 | 0.89 | FOLH1 (0.42) | FOLH1CPB2C3AR1PRSS1PRSS2 | |
| SCHEMBL24058460 | 0.89 | FOLH1 (0.38) | FOLH1CPB2VSIRPRSS1PRSS2 | |
| SCHEMBL24595229 | 0.89 | FOLH1 (0.38) | FOLH1CPB2VSIRPRSS1PRSS2 | |
| SCHEMBL24058564 | 0.89 | FOLH1 (0.38) | FOLH1CPB2VSIRPRSS1PRSS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-05-11 | — | — | US | disclosed |
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2023-01-24 | — | — | US | disclosed |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | AURIGENE ONCOLOGY LIMITED (IN) | 2021-05-13 | — | — | US | disclosed |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2019-07-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560403-B2 | 1,2,4-oxadiazole compounds as inhibitors of CD47 signaling pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3099/4885CPB2 4496/4885C3AR1 3699/4885 |
| US-20230144653-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3303/4885CPB2 4542/4885C3AR1 3540/4885 |
| US-20210139536-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling Pathways | CD47, HIF1AN, PIK3R5 | FOLH1 3303/4885CPB2 4542/4885C3AR1 3540/4885 |
| US-20190218252-A1 | 1,2,4-Oxadiazole Compounds as Inhibitors of CD47 Signalling | CD47, HIF1AN, PIK3R5 | FOLH1 3156/4885CPB2 4537/4885C3AR1 3582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.